1 From Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Wisconsin Carbone Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Moffitt Cancer Center; Fox Chase Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Memorial Sloan Kettering Cancer Center; Duke Cancer Institute; University of Washington/Seattle Cancer Care Alliance; City of Hope Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Michigan Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Roswell Park Cancer Institute; and National Comprehensive Cancer Network.
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
Provided content development and/or authorship assistance.